# Dose Selection Study of Efficacy and Safety of Different Doses of Grass MATA MPL and Grass MATA Using mEECs™

> **NCT02582073** · PHASE2 · COMPLETED · sponsor: **Allergy Therapeutics** · enrollment: 265 (actual)

## Conditions studied

- Seasonal Allergic Rhinitis

## Interventions

- **BIOLOGICAL:** Placebo (0.5ml)
- **BIOLOGICAL:** Placebo (1.0ml)
- **BIOLOGICAL:** Grass MATA MPL (0.5ml) 5100SU
- **BIOLOGICAL:** Grass MATA MPL (1.0ml) 10200SU
- **BIOLOGICAL:** Grass MATA MPL (1.0ml) 18200SU
- **BIOLOGICAL:** Grass MATA (0.5ml) 5100SU

## Key facts

- **NCT ID:** NCT02582073
- **Lead sponsor:** Allergy Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-07
- **Primary completion:** 2016-05-05
- **Final completion:** 2017-04-28
- **Target enrollment:** 265 (ACTUAL)
- **Last updated:** 2021-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02582073

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02582073, "Dose Selection Study of Efficacy and Safety of Different Doses of Grass MATA MPL and Grass MATA Using mEECs™". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT02582073. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*